Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could predict which eye treatments work best for Diabetes-Related vision loss

NCT ID NCT07707856

Knowledge-focused Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study reviews published research on artificial intelligence models that analyze retinal images to predict how well patients with diabetic macular edema will respond to treatments like anti-VEGF injections or laser therapy. By evaluating the accuracy of these AI tools, the review aims to identify the most promising imaging biomarkers and methods. The goal is to help doctors choose the right treatment for each patient, reducing vision loss and improving outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this review could identify reliable AI tools to personalize DME treatment, improving vision outcomes and reducing trial-and-error in therapy selection.
What could go wrong
As a systematic review of existing studies, it does not test new treatments directly. The findings depend on the quality and consistency of the included research, which may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,284 people

The number who actually took part.

Started

May 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with diabetic macular edema (DME) who underwent retinal imaging and received treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF), intravitreal corticosteroids, laser photocoagulation, or combination therapy. Eligible participants have baseline and follow-up clinical data, including best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and/or optical coherence tomography angiography (OCTA) images suitable for artificial intelligence-based analysis to predict anatomical and functional treatment response.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Diagnosis of diabetic macular edema (DME) confirmed by clinical examination and optical coherence tomography (OCT). * Treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF), intravitreal corticosteroids, focal/grid laser photocoagulation, or combination therapy. * Availability of baseline retinal imaging, including OCT, OCT angiography (OCTA), fundus photography, or multimodal imaging suitable for artificial intelligence analysis. * Availability of baseline and follow-up best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measurements. * Complete demographic and clinical data required for model development or validation. * Minimum follow-up of 3 months after initiation of treatment. Exclusion Criteria: * Macular edema due to causes other than diabetes. * Previous vitreoretinal surgery in the study eye. * Coexisting retinal diseases that may affect visual or anatomical outcomes (e.g., retinal vein occlusion, age-related macular degeneration, uveitis, inherited retinal disorders). * Significant media opacity resulting in poor-quality retinal imaging. * Incomplete clinical records or missing imaging data. * Follow-up duration less than 3 months. * Images that fail quality-control criteria for artificial intelligence analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic macular edema (DME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic macular edema (DME) Diabetic retinopathy

Contacts and locations

Locations

  • Benha University

    Banhā, Benha, 13111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.